Loading patent…
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsPaul F. Robbins, Steven A. Rosenberg, Xin Yao
Estimating the term…
The invention provides an isolated or purified T-cell receptor (TCR) having antigenic specificity for MHC Class II-restricted MAGE-A3. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a mammal are further provided by the invention.
1-2. (canceled)
The antibody, or antigen binding portion thereof, of claim 32, wherein the TCR or functional variant comprises:
The antibody, or antigen binding portion thereof, of claim 32, wherein the TCR or functional variant comprises a murine constant region.
The antibody, or antigen binding portion thereof, of claim 32, wherein the TCR or functional variant comprises:
11-31. (canceled)
An antibody, or antigen binding portion thereof, which specifically binds to a functional portion of a TCR or functional variant of the TCR, wherein the TCR and functional variant have antigenic specificity for MAGE-A3243-258 and MAGE-A6 and the functional portion comprises
Dependencies are inferred from the claim text.